Assembly Biosciences (ASMB) Income from Continuing Operations (2010 - 2026)
Assembly Biosciences (ASMB) posted quarterly Income from Continuing Operations of 11697000.0 for Q1 2026, down 17.17% year-over-year from 14121556.54 in Q1 2025, and down 152.95% quarter-over-quarter from 22090000.0 in Q4 2025.
Assembly Biosciences (ASMB) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Assembly Biosciences' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 11697000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 17.17% year-over-year to 11697000.0; the TTM figure through Mar 2026 stood at 9001000.0 (up 78.09% YoY), while the FY2025 annual figure was 6122000.0, up 84.76% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 11697000.0, down from 22090000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 22090000.0 in Q4 2025, with the low at 24704000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 11152000.0 (2024), against an average of 12718941.18.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations jumped 313.74% in 2025, then retreated 17.17% in 2026.
- Assembly Biosciences' Income from Continuing Operations stood at 24154000.0 in 2022, then surged by 54.62% to 10962000.0 in 2023, then increased by 5.72% to 10335000.0 in 2024, then soared by 313.74% to 22090000.0 in 2025, then sank by 152.95% to 11697000.0 in 2026.
- Business Quant data shows ASMB's Income from Continuing Operations at 11697000.0 in Q1 2026, 22090000.0 in Q4 2025, and 9196000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | -3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.86 Mn |
| Mar 31, 2026 | -11.70 Mn |
| Dec 31, 2025 | 22.09 Mn |
| Sep 30, 2025 | -9.20 Mn |
| Jun 30, 2025 | -10.20 Mn |
| Mar 31, 2025 | -9.98 Mn |
| Dec 31, 2024 | -10.34 Mn |
| Sep 30, 2024 | -9.61 Mn |
| Jun 30, 2024 | -11.15 Mn |
| Mar 31, 2024 | -9.08 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | -14.42 Mn |
| Jun 30, 2023 | -16.90 Mn |
| Mar 31, 2023 | -19.27 Mn |
| Dec 31, 2022 | -24.15 Mn |
| Sep 30, 2022 | -23.40 Mn |
| Jun 30, 2022 | -24.70 Mn |
| Mar 31, 2022 | -23.25 Mn |
| Dec 31, 2021 | -63.72 Mn |
| Sep 30, 2021 | -26.96 Mn |